EP Patent

EP3661503A1 — Antifungal agents with enhanced activity in acidic ph

Assigned to Scynexis Inc · Expires 2020-06-10 · 6y expired

What this patent protects

The triterpenoid antifungal compounds derived from enfumafungin are used to treat or prevent fungal infections occurring under or under acidic conditions, where the pH is less than about 7, because their efficacy is unexpectedly improved under such conditions. conditions. Triterp…

USPTO Abstract

The triterpenoid antifungal compounds derived from enfumafungin are used to treat or prevent fungal infections occurring under or under acidic conditions, where the pH is less than about 7, because their efficacy is unexpectedly improved under such conditions. conditions. Triterpenoids derived from enfumafungin (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3) -β-D-glucan synthesis and are useful in the treatment or prevention of infections. yeast or filamentous fungi that develop in low pH anatomical areas, such as the vaginal cavity, or under acidic local environment conditions such as those observed in fungal abscesses, in empyema, or in infections of the upper gastrointestinal tract.

Drugs covered by this patent

Patent Metadata

Patent number
EP3661503A1
Jurisdiction
EP
Classification
Expires
2020-06-10
Drug substance claim
No
Drug product claim
No
Assignee
Scynexis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.